GMO

Est. 1977
201-500 employees Investment Management

About GMO

For more than 40 years, GMO has partnered with a broad range of sophisticated institutions, financial intermediaries, and families to provide the investment expertise they need to meet their goals and fulfill their missions.

Investing on behalf of our clients is GMO’s sole focus. Across asset classes and around the world, our investment teams identify and exploit long-term opportunities and develop solutions that both anticipate and respond to client needs.

GMO is comprised of a collection of investment teams with focused specialties. All are grounded in a long-term, valuation-based investment philosophy – an approach we believe provides the best risk-adjusted returns.

GMO partners with an impressive roster of sophisticated clients worldwide, delivering innovative investment solutions and tailored client service. Our clients benefit from our diverse expertise, intellectual curiosity, and open culture of debate, as well as from our ability and willingness to take advantage of contrarian market opportunities.

For important disclosure information please visit: https://www.gmo.com/americas/terms-and-conditions/

JAPAN’S NEXT PHASE OF CORPORATE GOVERNANCE RE...
  • 04 Jun 2026

Japan’s corporate governance reforms are entering a new phase aimed squarely at how companies put capital to work. We examine what that means for investors and why active engagement still matters.

JAPAN EQUITIES
  • 28 May 2026

Structural reforms, rising earnings, and attractive valuations suggest Japanese equities still offer meaningful upside despite strong recent returns.

DIVERSIFYING BEYOND 60/40 WITH A MORE DYNAMIC...
  • 27 May 2026

Many still treat 60/40 as a neutral starting point. But after years of market gains, that “default” mix can embed unintended concentration in expensive U.S. growth and credit risk with limited spre...

PART 1: WHAT BARBARIANS LIKE TO TAKE PRIVATE
  • 21 May 2026

Research shows that private equity portfolios skew toward smaller, lower-quality companies, increasing downside risk. Ben Inker and John Pease explain how to hedge the resulting bias more effectively.

PART 2: LETTER TO THE INVESTMENT COMMITTEE ON...
  • 21 May 2026

Ben Inker pens a letter to the Investment Committee addressing the erosion of private equity performance persistence and its implications for institutions with meaningful private equity exposure.

GMO 7-YEAR ASSET CLASS FORECAST: APRIL 2026
  • 20 May 2026

GMO's 7-Year Asset Class Forecast as of April 30, 2026.

THE CASE FOR LIQUID ALTERNATIVES IN TODAY’S E...
  • 13 May 2026

Traditional portfolios face rising correlations and shared risks. We explore how liquid alternatives can provide differentiated return drivers, portfolio flexibility, and a more resilient diversifi...

THE CASE FOR ACTING NOW IN INTERNATIONAL DEEP...
  • 06 May 2026

Value is back, but selection matters. We show why the cheapest 20% of developed ex U.S. stocks look unusually mispriced, and how a framework incorporating quality can help avoid traps.

By GMO In Equities
HOW A “BIG BET” REMAINS POISED FOR FUTURE OUT...
  • 30 Apr 2026

International deep value remains attractively priced and is a high-conviction, active position across all GMO Asset Allocation portfolios.